A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Dr. I.D. Rusen, MD, of the MRC will present the preliminary results from Stage 1 of the STREAM randomized clinical trial on Thursday, December 14th from 10:00 – 11:00 EST (16:00 – 17:00 CET; 17:00 – 18:00 SAST). These results have been eagerly awaited and were first made public at the Union meeting last month in Guadalajara. If you missed hearing them then, be sure to sign on for this Webinar!
The STREAM Clinical Trial team, including Andrew Nunn and Patrick Philips (Medical Research Council’s Clinical Trials Unit at UCL) and I.D. Rusen (The Union/Vital Strategies), will present the preliminary results from Stage 1 of the STREAM randomized clinical trial. These results have been eagerly awaited and were first made public at the Union meeting last month in Guadalajara. If you missed hearing them then, be sure to sign on for this Webinar!
To join the event as an attendee
1. Go to https://hms.webex.com/hms/onstage/g.php?MTID=e504d6417ba22ecf4381c67b90c5543e0
2. Click “Join Now”.
To join the audio conference only
Call-in toll number (US/Canada): 1-408-792-6300
Global call-in numbers: https://hms.webex.com/hms/globalcallin.php?serviceType=EC&ED=598639627&tollFree=0
Toll-free dialing restrictions: https://www.webex.com/pdf/tollfree_restrictions.pdf
Access code: 710 578 617
To contact your host, RESIST-TB, send a message to firstname.lastname@example.org or email@example.com
The playback of UCF (Universal Communications Format) rich media files requires appropriate players. To view this type of rich media files in the meeting, please check whether you have the players installed on your computer by going to https://hms.webex.com/hms/onstage/systemdiagnosis.php
IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.
Recent News and Announcements
Drug-resistant tuberculosis cases are on the rise in Russia, India, the Philippines, and South Africa and expected to increase through 2040. Additional strategies to prevent transmission will be necessary to stop multidrug-resistant or extensively drug-resistant tuberculosis in countries with a high burden of MDR tuberculosis. Watch the video found here to find out more.
“The start of 2017 saw concern over a sharp increase in the rise of drug-resistant TB in South Africa. TB is killing millions each year. Last week, Médecins Sans Frontières published promising early data on the use of two new TB drugs, delamanid and bedaquiline, among patients living with drug-resistant TB in Khayelitsha, Cape Town. […]
“Preliminary results – released at the 48th Union Conference on Lung Health – from Stage 1 of the STREAM randomized clinical trial show that the nine-month treatment regimen being tested achieved favorable outcomes in almost 80 percent of those treated.The results suggest the nine-month regimen is very close to the effectiveness of the 20-24 month regimen […]
Article by Betsy McKay, published in the Wall Street Journal, 13 Oct 2017 7:00 A.M. ET New research released this week bolsters the case for more effective, less toxic and shorter treatment regimens for drug-resistant tuberculosis, offering hope for patients suffering from a disease that is notoriously difficult to treat. The three separate studies […]
“Saint Louis University is leading a multi-national clinical trial of what could become a regimen for drug resistant tuberculosis that does not require injectable medications. The project is funded by a $6.4 million task order from the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health. Saint Louis University, […]